[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[N:3]=[C:2]1[C:10]1[C:11]([Cl:30])=[N:12][C:13]([CH:17]2[CH2:22][CH2:21][N:20](C(OC(C)(C)C)=O)[CH2:19][CH2:18]2)=[N:14][C:15]=1[OH:16].Cl>CO>[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[N:3]=[C:2]1[C:10]1[C:15]([OH:16])=[N:14][C:13]([CH:17]2[CH2:18][CH2:19][NH:20][CH2:21][CH2:22]2)=[N:12][C:11]=1[Cl:30]Into a solution of tert-butyl 4-[5-(1,3-benzothiazol-2-yl)-4-chloro-6-hydroxypyrimidin-2-yl]piperidine-1-carboxylate (44.7 g, 100.01 mmol, 1.00 equiv) in methanol (50 ml) was added concentrated hydrochloric acid (50 mL, 12 M). The resulting solution was stirred for 30 min at room temperature. Concentration under vacuum gave 34 g of 5-(1,3-benzothiazol-2-yl)-6-chloro-2-(piperidin-4-yl)pyrimidin-4-ol as a yellow solid, which was used directly for next step without further purification. MS m/z [M+H](ESI): 347.